PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
MEMORANDUM
October 14, 2022
To: Leonard Cross, Responsible Partner Sylvia Hartwell, Billing Partner Garrett Simmons, Lead Associate
From: Leila Nazari, Working Associate
Re: Analysis of GILTI and BEAT Interaction with IRS Proposed IRC § 482 Adjustments — Penterra Pharmaceuticals Corp. (TY 2018–2020)
Matter No.: 1018-00009
Client: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to analyze how the Internal Revenue Service's proposed transfer pricing adjustments under Section 482 of the Internal Revenue Code ("IRC") for tax years ("TY") 2017 through 2020 interact with Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") positions under the Global Intangible Low-Taxed Income provisions of IRC § 951A ("GILTI") and the Base Erosion and Anti-Abuse Tax provisions of IRC § 59A ("BEAT") for TY 2018 through 2020. TY 2017 is largely pre-Tax Cuts and Jobs Act ("TCJA") — subject to the 35% corporate rate with no GILTI or BEAT provisions in effect — and is accordingly excluded from the core of this analysis, except where transitional observations are warranted for purposes of settlement allocation strategy.
The IRS's proposed adjustments under IRC § 482, as set forth in the Notice of Proposed Adjustment ("NOPA"), total $380.4 million (net) across all years at issue. These adjustments comprise cost-sharing arrangement ("CSA") cost-sharing increases of $235.01 million, royalty rate adjustments of $188.04 million, less a correlative offset of $42.65 million allowed by the examination team to avoid double-counting. The proposed adjustments also carry a proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million (computed as $380.4 million × 21% × 20%).
Key Conclusion. If the IRS's proposed § 482 adjustments were sustained in full, the adjustments would paradoxically reduce PPC's GILTI inclusion while potentially triggering or increasing BEAT liability. However, upon detailed analysis, the BEAT risk is minimal given PPC's inbound-payment intercompany structure, whereas the GILTI offset is substantial and material. These cross-currents create both offensive and defensive opportunities in the examination and at the Appeals stage.
More specifically, the GILTI offset reduces the net incremental U.S. tax cost of the proposed adjustments by approximately 25–30% for TY 2018–2020. Each dollar of income shifted from Penterra Biopharma International DAC ("PBI") to PPC under the proposed adjustments increases PPC's U.S. taxable income at 21% but simultaneously reduces PPC's GILTI inclusion, which would otherwise be taxed at an effective rate of approximately 5.5% to 10.0% (depending on PBI's blended Irish effective rate and the operation of the 80% foreign tax credit limitation under IRC § 960). The net effective incremental rate on the proposed adjustments for TY 2018–2020 is therefore approximately 11% to 15.5%, rather than the nominal 21%.
The BEAT analysis confirms that PPC's intercompany payment structure — in which the predominant cash flows run inbound from the Irish entities to PPC (cost-sharing payments and royalty payments from PBI to PPC), rather than outbound from PPC to related foreign persons — results in minimal or no BEAT exposure. PPC's base erosion percentage is preliminarily assessed as falling below the 3% statutory threshold, which would exempt PPC from BEAT entirely for the years at issue.
These dynamics should be integrated into all financial modeling, settlement range analysis, and Appeals strategy presentations going forward.
It bears noting that PPC was not in the Compliance Assurance Process ("CAP") for the years at issue, and accordingly these GILTI/BEAT interactions were not pre-cleared with the IRS Large Business & International ("LB&I") Division. The absence of a CAP determination means that the IRS examination team may not have fully modeled the GILTI/BEAT consequences of their proposed adjustments, a fact that may be leveraged constructively in Appeals proceedings.
The TCJA's effective date is January 1, 2018. PPC is a calendar-year taxpayer with a fiscal year ending December 31, meaning TY 2018 is the first full year subject to the reduced 21% corporate tax rate and the GILTI and BEAT regimes.
II. Background: PPC's International IP Structure
A. Corporate Structure
PPC is a Delaware corporation headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC's common stock trades on the Nasdaq Global Select Market under the ticker symbol "PPCA." PPC is a publicly traded pharmaceutical company with global operations focused on oncology, immunology, and rare disease therapeutics.
PPC's international intellectual property structure is organized as follows:
PPC (Delaware corporation; U.S. parent)
→ Penterra Holdings Luxembourg S.à r.l. ("PHL"), 14, rue Aldringen, L-1118 Luxembourg; Registre de Commerce et des Sociétés ("RCS") No. B 168452. PHL is a Luxembourg private limited liability company and is treated as a disregarded entity for U.S. federal income tax purposes under Treas. Reg. § 301.7701-3.
→ Penterra Biopharma International DAC ("PBI"), 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland; Irish Tax Reference No. 3218764T. PBI is a Designated Activity Company organized under Irish law and is the principal non-Americas commercial entity within the Penterra group.
PBI is a controlled foreign corporation ("CFC") of PPC within the meaning of IRC § 957(a). PPC is the sole United States shareholder of PBI within the meaning of IRC § 951(b), holding 100% of PBI's outstanding shares through the disregarded entity PHL. Because PHL is disregarded for U.S. federal tax purposes, PPC is treated as owning PBI directly for purposes of the subpart F, GILTI, and other CFC-related provisions of the Code.
In addition to PBI, the relevant international entity is:
Penterra Manufacturing Ireland Ltd. ("PMI"), Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland; Companies Registration Office ("CRO") No. 512347. PMI is an Irish limited company and a wholly owned subsidiary of PBI. PMI operates as a contract manufacturer under a cost-plus 8% arrangement with PBI.
PMI is a separate CFC of PPC (through PBI and PHL). PMI maintains significant physical operations in Ireland, employing approximately 620 employees at its Ringaskiddy manufacturing facility as of December 31, 2020. PMI's operations include active pharmaceutical ingredient ("API") production, formulation, fill-and-finish, and quality control for products commercialized by PBI outside the Americas.
B. Key Intercompany Arrangements
PPC's international IP structure rests on two principal intercompany arrangements between PPC and PBI:
Cost-Sharing Arrangement ("CSA"). Effective July 1, 2012, PPC and PBI entered into a qualified cost-sharing arrangement within the meaning of Treas. Reg. § 1.482-7. Under the CSA, PBI co-funds PPC's pharmaceutical R&D activities in exchange for the right to exploit the resulting intangible property outside the Americas (defined as North America, Central America, South America, and the Caribbean). PPC retains all rights to exploit the resulting IP within the Americas.
At inception, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC, reflecting the buy-in for the reasonably anticipated benefit from the pre-existing intangible property contributed by PPC to the CSA arrangement. The PCT payment was determined using a discounted cash flow methodology and was the subject of contemporaneous documentation prepared by Crestfield & Associates LLP, PPC's independent transfer pricing advisor.
PBI's cost-sharing percentages and dollar contributions for TY 2018–2020 were as follows:
PBI's increasing cost-sharing percentage reflects the growing proportion of reasonably anticipated benefits attributable to PBI's non-Americas territory, driven primarily by the expanding global commercial footprint of Veritaxol and Imvara in ex-Americas markets.
Legacy IP License. In addition to the CSA, PBI licenses from PPC certain pre-2012 pharmaceutical compounds and associated know-how that were not contributed to the CSA (i.e., intellectual property developed or in-licensed by PPC prior to July 1, 2012 that was excluded from the CSA arrangement). Under this license agreement, PBI pays PPC a royalty of 4.5% of non-Americas net sales of legacy compounds. The royalty rate was established in 2012 based on a comparable uncontrolled transaction ("CUT") analysis performed by Crestfield & Associates.
Non-Americas legacy compound net sales and corresponding royalty payments for TY 2018–2020 were:
The declining trajectory of legacy net sales reflects the life-cycle maturation of pre-2012 compounds, including generic entry in certain ex-Americas markets.
C. PBI Financials and Irish Tax Position
PBI is a substantial commercial entity with growing operational capability. As of fiscal year 2020:
• PBI's total revenue was €2.14 billion, derived from commercialization of Penterra's pharmaceutical products across non-Americas markets spanning 68 countries.
• PBI's pre-tax income was approximately €1.06 billion.
• PBI employed 185 individuals as of December 31, 2020, including commercial, medical affairs, regulatory, finance, and general management personnel. This represents significant growth from the 52 employees at PBI's incorporation in 2012.
• PBI's managing director is Aidan Naughton, who has served in that capacity since 2014 and is based full-time in Dublin.
• PBI's board of directors met 42 times during the period 2017–2020, reflecting active governance over PBI's commercial operations, strategic planning, and regulatory affairs.
• PBI maintained approximately 18,000 square feet of office space at the Sandyford Business Park in Dublin.
• PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the period, reflecting its active engagement with the European Medicines Agency ("EMA") and other non-Americas regulatory authorities.
With respect to Irish taxation, PBI is subject to the standard Irish trading income rate of 12.5% on qualifying trading income. Beginning in FY 2016, PBI also claims the benefit of Ireland's Knowledge Development box ("KDB") regime, which provides an effective rate of 6.25% on qualifying income attributable to qualifying intellectual property assets. PBI's blended effective Irish tax rate reflects a mix of 12.5% standard trading income and 6.25% KDB-qualifying income, depending on the proportion of income attributable to qualifying IP in each year.
PBI's Irish tax affairs are managed by Thornbury & Keogh, Chartered Tax Advisors, Dublin, under the supervision of lead partner Ciarán Thornbury.
D. IRS Proposed § 482 Adjustments
The IRS's proposed adjustments under IRC § 482, as set forth in the NOPA issued to PPC, consist of two principal categories of adjustments across TY 2017–2020:
CSA Cost-Sharing Adjustments. The IRS proposes to increase PBI's cost-sharing percentage under the CSA by approximately 11.0 to 11.2 percentage points for each year, asserting that PBI's reasonably anticipated benefits from the CSA intangibles are greater than reflected in PBI's reported cost-sharing percentages. The proposed increases and corresponding dollar amounts are:
Royalty Rate Adjustments. The IRS proposes to increase the royalty rate on the legacy IP license from 4.5% to 11.0% of non-Americas net sales, asserting that PPC's comparable uncontrolled transaction analysis understates the arm's-length royalty rate for the licensed intangibles. The proposed adjustments are:
Correlative Offset. The IRS examination team has allowed a correlative offset of $42.65 million across all years to avoid double-counting between the CSA adjustments and the royalty rate adjustments, recognizing that a portion of the intangible value captured by the increased royalty rate overlaps with the value reflected in the increased cost-sharing percentage.
Net Proposed Adjustment. The net proposed adjustment across all four years is $380.4 million ($235.01M + $188.04M − $42.65M).
Proposed Penalty. The IRS has asserted an IRC § 6662(e) substantial valuation misstatement penalty of 20% on the underpayment of tax attributable to the § 482 allocation. The estimated penalty exposure is approximately $15.98 million, computed as $380.4 million × 21% × 20%. The penalty computation may vary by year based on the applicable tax rate (35% for TY 2017, 21% for TY 2018–2020).
The IRS examination team consists of Supervisory Revenue Agent Gerald Meskill, Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and Attorney-Advisor Franklin Rosario.
E. Key Products
PPC's pharmaceutical portfolio includes three major products that drive the overwhelming majority of revenue for both PPC (Americas) and PBI (non-Americas):
These three products account for the substantial majority of PBI's revenue and tested income for GILTI purposes, and their commercial trajectory in non-Americas markets is the primary driver of the intercompany pricing disputes at issue.
III. GILTI Analysis (IRC § 951A)
A. Overview of GILTI Framework
The GILTI provisions were enacted as part of the TCJA and are codified at IRC § 951A. GILTI is effective for taxable years of foreign corporations beginning after December 31, 2017, and for taxable years of United States shareholders in which or with which such taxable years of foreign corporations end. For PPC, a calendar-year taxpayer, GILTI applies beginning with TY 2018.
Under the GILTI regime, a United States shareholder of a CFC must include in gross income its pro rata share of the CFC's "global intangible low-taxed income." The GILTI inclusion is computed as follows:
GILTI = Net CFC Tested Income − Net Deemed Tangible Income Return ("DTIR")
Where:
• Net CFC Tested Income equals the excess of the aggregate of the shareholder's pro rata share of tested income of each CFC over the aggregate of the shareholder's pro rata share of tested loss of each CFC.
• Net DTIR equals 10% of the shareholder's pro rata share of the aggregate qualified business asset investment ("QBAI") of all CFCs, reduced by certain interest expenses.
The GILTI inclusion is treated as an amount received by the United States shareholder under IRC § 951(a)(1)(A) and is included in the shareholder's gross income for the taxable year.
IRC § 250 Deduction. Under IRC § 250(a)(1)(B), a domestic corporation is allowed a deduction equal to 50% of its GILTI inclusion amount for taxable years beginning after December 31, 2017 and before January 1, 2026 (the deduction decreases to 37.5% for taxable years beginning after December 31, 2025). The 50% deduction results in an effective U.S. tax rate on GILTI inclusions of 10.5% (21% × 50%) before the application of foreign tax credits.
IRC § 960 Deemed-Paid Foreign Tax Credits. Under IRC § 960(d), a domestic corporation that includes a GILTI amount in gross income is deemed to have paid 80% of the foreign income taxes paid or accrued by the CFC that are properly attributable to the tested income. The 80% haircut means that the full amount of foreign taxes paid by the CFC on its tested income does not offset the U.S. GILTI tax; only 80% is creditable. The deemed-paid credits are subject to the GILTI foreign tax credit limitation basket under IRC § 904(d)(1)(A).
B. PBI as PPC's CFC — Tested Income Computation
PBI is a CFC of PPC, and PPC is a United States shareholder holding 100% of PBI's stock (through the disregarded entity PHL). PPC is therefore required to include in its gross income its pro rata share of PBI's GILTI, which equals 100% of PBI's tested income (less DTIR).
PBI's "tested income" is computed as PBI's gross income minus allocable deductions, excluding the following categories of income that are carved out from tested income:
• Subpart F income (IRC § 951A(c)(2)(A)(i));
• Effectively connected income (IRC § 951A(c)(2)(A)(ii));
• Income excluded under the high-taxed exclusion of Treas. Reg. § 1.951A-2(c)(7) (if applicable);
• Dividends received from related persons; and
• Certain other carved-out categories specified in IRC § 951A(c)(2)(A).
PBI's substantial tested income is driven by its €2.14 billion (FY 2020) in revenue from the non-Americas commercialization of Veritaxol, Imvara, Cerulon, and legacy products. After deducting PBI's cost of goods sold (including cost-sharing payments to PPC and royalties paid to PPC under the legacy IP license), operating expenses, and other allocable deductions, PBI's tested income for each year is a significant positive amount.
High-Taxed Exclusion Analysis. Under Treas. Reg. § 1.951A-2(c)(7), a CFC's tested income may be excluded from the GILTI computation if the effective rate of foreign tax on such income exceeds 90% of the U.S. corporate tax rate. The threshold is 90% × 21% = 18.9%.
PBI's effective Irish tax rate is either 6.25% (on KDB-qualifying income) or 12.5% (on standard trading income). Both rates are well below the 18.9% threshold. Accordingly, the GILTI high-taxed exclusion is not available to PBI for any of the years at issue. All of PBI's tested income is included in PPC's GILTI computation.
C. Impact of § 482 Adjustments on GILTI Inclusion
The IRS's proposed § 482 adjustments affect PPC's GILTI computation in two ways: (1) they increase PPC's U.S. taxable income (through additional cost-sharing receipts and royalty receipts from PBI), and (2) they correspondingly decrease PBI's tested income (because PBI's deductible intercompany payments increase). The net tax effect depends on the rate differential between U.S. taxable income (21%) and the effective GILTI rate (10.5% before foreign tax credits, less after FTCs).
1. CSA Cost-Sharing Adjustments. The IRS proposes to increase PBI's cost-sharing payments to PPC under the CSA by the following amounts:
• 2018: $57.61 million (increase of 11.0 percentage points)
• 2019: $62.85 million (increase of 11.2 percentage points)
• 2020: $65.82 million (increase of 11.0 percentage points)
Effect on PBI's Tested Income. If the proposed adjustments are sustained, PBI's deductible R&D cost-sharing payments to PPC increase by the above amounts. These additional deductible payments reduce PBI's pre-tax income and, consequently, PBI's tested income for GILTI purposes. PBI's tested income for each year would decrease dollar-for-dollar by the amount of the additional cost-sharing payments (assuming such payments are fully deductible against PBI's tested income and are not allocable to any carved-out income category).
Effect on PPC's U.S. Taxable Income. Simultaneously, PPC's U.S. gross income increases by the additional cost-sharing payments received from PBI. These receipts are included in PPC's U.S. taxable income and are taxed at the 21% corporate rate.
Net GILTI Effect. PPC's GILTI inclusion decreases because PBI's tested income declines, but PPC's U.S. taxable income increases dollar-for-dollar. The net tax effect depends on the differential between the U.S. effective rate on the § 482 adjustment income (21%) and the GILTI effective rate on the displaced PBI income (10.5% after the § 250 deduction, minus deemed-paid foreign tax credits under IRC § 960).
Illustrative quantification for each year, subject to refinement based on full GILTI computations:
• TY 2018: Additional cost-sharing receipts to PPC: $57.61 million. U.S. tax on additional income at 21% = $12.10 million. Reduction in GILTI inclusion: PBI's tested income decreases by $57.61 million; at the effective GILTI rate of approximately 10.5% (before FTCs), the GILTI tax savings are approximately $6.05 million. Net incremental tax from CSA adjustment alone: approximately $6.05 million (before accounting for the interaction of FTCs and QBAI effects).
• TY 2019: Additional cost-sharing receipts: $62.85 million. U.S. tax increase: $13.20 million. GILTI reduction savings at 10.5%: approximately $6.60 million. Net incremental tax: approximately $6.60 million.
• TY 2020: Additional cost-sharing receipts: $65.82 million. U.S. tax increase: $13.82 million. GILTI reduction savings at 10.5%: approximately $6.91 million. Net incremental tax: approximately $6.91 million.
These computations are illustrative and will be refined once PPC's full GILTI computations (including QBAI and FTC calculations) are obtained from Marcus Whitfield and Crestfield & Associates.
2. Royalty Rate Adjustments. The IRS proposes to increase the royalty rate on PBI's legacy IP license from 4.5% to 11.0% of non-Americas net sales. The additional royalty payments from PBI to PPC would be:
• 2018: $49.55 million
• 2019: $44.97 million
• 2020: $40.57 million
Effect on PBI's Tested Income. PBI's deductible royalty expense to PPC increases by the above amounts, reducing PBI's pre-tax income and tested income correspondingly.
Effect on PPC. PPC receives additional royalty income, which is included in PPC's U.S. taxable income and taxed at 21%. Royalty income received from a CFC is generally characterized as U.S.-source income for purposes of the U.S. tax computation.
Treaty Withholding Tax Consideration. The royalty payments from PBI (an Irish entity) to PPC (a U.S. entity) are subject to the U.S.-Ireland Income Tax Treaty. Under Article 12 of the Treaty, royalties paid by an Irish resident to a U.S. resident are generally exempt from Irish withholding tax (0% rate). Accordingly, no Irish withholding tax is imposed on the royalty payments, and no foreign tax credit issue arises at the withholding level. The relevant foreign tax credit computation for GILTI purposes relates to the Irish corporate income tax paid by PBI on its tested income, not withholding tax on the royalty payments.
The quantification of the GILTI offset from the royalty adjustments follows the same analytical pattern as the CSA adjustments: each dollar of additional royalty income is taxed at 21% in the United States, while the corresponding reduction in PBI's tested income reduces GILTI tax at the effective GILTI rate (10.5% before FTCs, less after FTCs).
3. Correlative Offset. The IRS examination team has allowed a correlative offset of $42.65 million across all years to avoid double-counting between the CSA cost-sharing adjustments and the royalty rate adjustments. This offset reduces both the net increase in PPC's U.S. taxable income and the corresponding net decrease in PBI's tested income, proportionally reducing both the incremental U.S. tax and the GILTI offset. The year-by-year allocation of the $42.65 million correlative offset has not been precisely specified in the NOPA and should be confirmed with the examination team or through review of the adjustment workpapers.
4. QBAI and DTIR Considerations. PBI's QBAI consists of the adjusted tax basis of depreciable tangible property used in PBI's trade or business, determined under the alternative depreciation system ("ADS") of IRC § 168(g). PBI is primarily an IP-holding and commercial entity; its tangible asset base is relatively modest, consisting principally of office furniture, computer equipment, leasehold improvements at the Sandyford Business Park location, and a small amount of laboratory equipment.
The more significant tangible asset base within the Penterra international structure resides at PMI, which operates the Ringaskiddy manufacturing facility with substantial manufacturing equipment, building improvements, and other depreciable tangible property. However, PMI is a separate CFC, and its QBAI is tested separately from PBI's for GILTI purposes. PMI's limited profitability under its cost-plus 8% arrangement with PBI means that PMI generates modest tested income, and its QBAI generates a DTIR that largely or entirely offsets PMI's tested income, resulting in minimal GILTI contribution from PMI.
Impact of § 482 Adjustments on QBAI. The proposed § 482 adjustments have no direct effect on PBI's QBAI, because QBAI is determined by reference to the adjusted tax basis of depreciable tangible property, not by reference to income or deductions. However, because the proposed adjustments reduce PBI's tested income without changing PBI's QBAI, they increase the relative DTIR offset as a proportion of tested income. If PBI's tested income declines while its QBAI (and therefore its DTIR) remains constant, the GILTI inclusion (tested income minus DTIR) declines by more than the raw reduction in tested income in percentage terms. This effect is modest in PBI's case given PBI's relatively low QBAI, but it provides a marginal additional GILTI benefit from the § 482 adjustments.
D. IRC § 960 Foreign Tax Credit Impact
PBI pays Irish corporate income tax on its tested income at either 6.25% (on income qualifying for the Knowledge Development box) or 12.5% (on standard trading income not qualifying for the KDB). The blended effective Irish rate depends on the proportion of PBI's income qualifying for the KDB in each year.
If PBI's tested income decreases as a result of the proposed § 482 adjustments (through higher deductible cost-sharing payments and royalty payments to PPC), the Irish corporate income taxes attributable to that tested income also decrease. PBI will pay less Irish tax because its Irish taxable income declines.
Under IRC § 960(d), the deemed-paid foreign tax credits available to PPC are limited to 80% of the foreign income taxes paid by PBI that are properly attributable to PBI's tested income. The 80% haircut means that PPC never fully credits PBI's Irish taxes against its GILTI liability.
Net Effect. The reduction in PBI's tested income produces two partially offsetting effects: (1) a reduction in PPC's GILTI inclusion (beneficial to PPC), and (2) a reduction in the deemed-paid foreign tax credits available to offset the remaining GILTI inclusion (adverse to PPC). The FTC impact partially offsets the GILTI reduction benefit, but does not eliminate it.
Estimated Effective GILTI Rate After FTCs. The effective residual U.S. GILTI tax depends on PBI's blended Irish effective rate:
• At 6.25% KDB rate: Deemed-paid FTC = 80% × 6.25% = 5.0% effective credit rate. Compared against the 10.5% GILTI rate (after § 250 deduction), the residual U.S. GILTI tax is 10.5% − 5.0% = 5.5%.
• At 12.5% standard trading rate: Deemed-paid FTC = 80% × 12.5% = 10.0% effective credit rate. Residual U.S. GILTI tax is 10.5% − 10.0% = 0.5%.
Implication. Income taxed at the 6.25% KDB rate bears substantially more residual U.S. GILTI tax (5.5%) than income taxed at the 12.5% standard rate (0.5%). Consequently, § 482 adjustments that reduce PBI's KDB-taxed income generate more GILTI tax savings per dollar of adjustment than adjustments to income taxed at the 12.5% standard rate. The composition of PBI's income between KDB-qualifying and non-qualifying income is therefore a critical variable in the quantitative model and must be obtained from PBI's Irish tax computations and from Thornbury & Keogh.
E. Strategic Implications for Defense
The GILTI offset partially mitigates the U.S. tax cost of the proposed § 482 adjustments. For each dollar of income shifted from PBI to PPC under the proposed adjustments, PPC's U.S. taxable income increases by one dollar (taxed at 21%), but PPC's GILTI inclusion decreases by approximately one dollar (saving tax at approximately 5.5% to 10.0%, depending on PBI's blended Irish effective rate). The net incremental U.S. tax rate on each dollar of the proposed adjustment is therefore approximately 11% to 15.5%, rather than the full 21% statutory rate.
This dynamic creates several strategic opportunities:
First, the GILTI offset provides a "softening" argument at Appeals. The true revenue impact to the government from the proposed § 482 adjustments is less than the nominal adjustment amount × 21% suggests. To the extent the assigned Appeals Officer — Noreen Castañeda, assigned January 2024 — considers the revenue at stake in calibrating settlement, the GILTI offset reduces the effective stakes. While Appeals Officers are trained to evaluate transfer pricing adjustments on their legal and factual merits independent of downstream tax consequences, the practical reality is that the magnitude of the tax at stake influences the intensity and duration of Appeals proceedings and the contours of settlement discussions.
Second, the GILTI offset can be quantified in the sensitivity analysis prepared for settlement range modeling. We recommend incorporating the GILTI offset at multiple settlement levels (see Part V.C below) to provide the engagement team and the client with a clear picture of the effective cost at each potential settlement point.
Third, however, we note an important caveat: the IRS examination team (Supervisory Revenue Agent Meskill, Lead Revenue Agent Dunleavy, IRS Economist Dr. Washburne, and Attorney-Advisor Rosario) may view the GILTI offset as entirely irrelevant to the arm's-length determination under IRC § 482. The arm's-length standard is a legal and factual inquiry into whether the terms of the intercompany transactions are consistent with those that would have been agreed upon by unrelated parties dealing at arm's length. The downstream U.S. tax consequences of the pricing determination — including GILTI and BEAT effects — do not bear on the factual question of what unrelated parties would have charged. Accordingly, the GILTI argument is more appropriately deployed as a contextual or policy-level argument at Appeals, rather than as a defense to the merits of the § 482 adjustment.
We recommend that the GILTI offset quantification be included in the sensitivity analysis workbook and in Appeals presentations, while being careful not to conflate the GILTI argument with the substantive arm's-length defense.
IV. BEAT Analysis (IRC § 59A)
A. Overview of BEAT Framework
The Base Erosion and Anti-Abuse Tax ("BEAT") was enacted by the TCJA and is codified at IRC § 59A. BEAT is effective for taxable years beginning after December 31, 2017.
BEAT imposes a minimum tax on "applicable taxpayers" — defined as U.S. corporations (or groups filing consolidated returns) that satisfy two requirements:
1. Gross Receipts Test: The taxpayer has average annual gross receipts of at least $500 million for the three-taxable-year period ending with the preceding taxable year (IRC § 59A(e)(1)(A)); and
2. Base Erosion Percentage Test: The taxpayer has a "base erosion percentage" of 3% or more for the taxable year (IRC § 59A(e)(1)(B)) (2% for certain banks and registered securities dealers).
PPC's FY 2020 revenue was $6.82 billion, far exceeding the $500 million gross receipts threshold. PPC satisfies the gross receipts test for each year at issue. The critical question for BEAT applicability is whether PPC meets the base erosion percentage threshold.
BEAT Tax Computation. If both tests are met, the BEAT tax is computed as follows:
BEAT Tax = [BEAT Rate × Modified Taxable Income ("MTI")] − [Regular Tax Liability + Certain Credits]
BEAT tax is payable only to the extent the computation yields a positive amount — i.e., only to the extent the BEAT minimum tax exceeds the taxpayer's regular tax liability (plus applicable credits).
Modified Taxable Income ("MTI") is the taxpayer's taxable income computed without regard to (i) deductions for "base erosion payments" made to related foreign parties, and (ii) the base erosion percentage of any net operating loss deduction.
BEAT Rates. The applicable BEAT rates are:
• TY 2018: 5% (first year of applicability)
• TY 2019–2025: 10%
• TY 2026 and thereafter: 12.5%
B. Base Erosion Payments — Identification
The threshold question for PPC's BEAT analysis is the identification of "base erosion payments" — amounts paid or accrued by the taxpayer to related foreign persons with respect to which a deduction is allowable under the Code (IRC § 59A(d)(1)). The analysis must examine each category of intercompany payment flowing from PPC to its related foreign entities.
1. Royalty Payments (Legacy IP License). Under the Legacy IP License, PBI pays royalties to PPC — that is, the cash flow direction is from PBI (the Irish entity) to PPC (the U.S. parent). PPC is the recipient of the royalty payments, not the payor. These inbound royalty payments increase PPC's U.S. taxable income.
The Legacy IP royalty payments are therefore not base erosion payments from PPC's perspective. BEAT applies to deductible payments made by the U.S. taxpayer to related foreign persons. The legacy royalty payments flow in the opposite direction (PBI → PPC) and do not give rise to any deduction for PPC.
If the IRS's proposed adjustments increase the royalty rate from 4.5% to 11.0%, PPC receives more royalty income from PBI, which increases PPC's taxable income without any corresponding BEAT implication.
2. Cost-Sharing Payments Under the CSA. Under the CSA, PBI makes cost-sharing payments to PPC as PBI's share of qualified R&D costs. These payments are inbound to PPC. PPC also funds its own share of R&D costs (the Americas share), but PPC's R&D expenditures are incurred domestically to fund R&D performed primarily in the United States at PPC's Princeton Junction research campus and its satellite R&D facilities.
The question is whether any portion of PPC's R&D spending that benefits PBI's non-Americas territory constitutes a base erosion payment from PPC to PBI.
Under Treas. Reg. § 1.59A-3(b)(3)(iii), amounts paid or accrued by the taxpayer to a related foreign party that are treated as reductions to gross income (rather than as deductions) are generally not base erosion payments. Cost-sharing receipts received by PPC from PBI under the CSA are treated as reductions to PPC's R&D expense pool — they offset PPC's gross R&D spending and are not separately characterized as gross income items for purposes of the base erosion payment analysis. Accordingly, the CSA cost-sharing payments do not give rise to base erosion payments from PPC.
The proposed § 482 adjustments increase the amounts deemed received by PPC from PBI under the CSA. This further reduces PPC's net R&D deduction (or increases PPC's income) and does not create a base erosion payment. To the contrary, the adjustments operate in the opposite direction from a BEAT perspective — they increase PPC's income rather than creating outbound deductible payments.
An important caveat warrants mention: if the IRS were to recharacterize the CSA arrangement entirely — for example, by treating the CSA as a license arrangement with PPC as licensor receiving inadequate royalties — the analysis could shift. However, the NOPA as issued does not recharacterize the CSA in this manner. The NOPA proposes adjustment of the cost-sharing percentages within the existing CSA framework, increasing PBI's payments to PPC rather than identifying any outbound payments from PPC to PBI. Accordingly, BEAT exposure from the CSA is not directly at issue under the current NOPA.
3. PMI Contract Manufacturing Payments. PMI (the Irish contract manufacturer, 620 employees) manufactures pharmaceutical products for PBI under a cost-plus 8% arrangement. PBI pays PMI for the manufacturing services; PPC does not directly contract with or pay PMI.
The question is whether any portion of PPC's consolidated return includes direct or imputed payments to PMI that could constitute base erosion payments. Upon analysis:
• PMI contracts with PBI, not PPC. PPC does not directly deduct any amounts payable to PMI on its U.S. federal income tax return.
• To the extent PBI's cost-sharing payments to PPC embed PMI manufacturing costs (because PBI's cost of goods sold includes amounts paid to PMI), the payment direction remains PBI → PPC (inbound). PPC does not make outbound deductible payments related to PMI's manufacturing services.
• The PMI cost-plus payments are payments from PBI to PMI — related-party payments between two Irish entities — and do not directly impact PPC's BEAT computation. While these payments affect PBI's pre-tax income (and hence PBI's tested income for GILTI purposes), they are not base erosion payments from PPC.
4. Other Potential Base Erosion Payments. We have reviewed the intercompany agreement matrix maintained by PPC's Global Tax Department (as provided by Marcus Whitfield on August 3, 2022) to identify any other potentially deductible payments made by PPC to PBI, PHL, PMI, or any other related foreign persons. Based on this review:
• PPC does not appear to make material management fee, service fee, or administrative charge payments to any of the Irish entities. Management and administrative services flow from PPC to PBI (with PBI reimbursing PPC at cost or cost-plus, constituting inbound payments to PPC).
• PPC does not pay royalties or license fees to PBI or any other related foreign entity. The royalty flow is exclusively PBI → PPC.
• PPC does not make interest payments to the Irish entities. PHL (the Luxembourg entity) does not hold intercompany debt from PPC.
• PPC may make certain de minimis payments to foreign affiliates for secondment arrangements, data processing services, or other incidental items, but these are not expected to be material for BEAT purposes.
Based on the foregoing analysis, the primary intercompany cash flows between PPC and its related foreign entities are inbound to PPC, not outbound. PPC is predominantly a net recipient of intercompany payments from its Irish entities, reflecting the structure's design in which PBI funds R&D through cost-sharing and pays royalties to PPC for legacy IP.
C. Base Erosion Percentage Computation
The base erosion percentage is computed as follows:
Base Erosion Percentage = Base Erosion Tax Benefits ÷ Total Deductions (with certain exclusions)
"Base erosion tax benefits" are the deductions that are allowed under the Code with respect to base erosion payments, plus certain other items. "Total deductions" include all deductions allowed in computing taxable income, with exclusions for the § 172 net operating loss deduction, the § 199A deduction, the § 250 deduction, and certain other items specified in IRC § 59A(c)(4).
If PPC's base erosion tax benefits (i.e., deductions attributable to payments to related foreign parties) are minimal relative to its total deductions, PPC's base erosion percentage may fall below the 3% statutory threshold. If the base erosion percentage is below 3%, PPC is not an "applicable taxpayer" and is exempt from BEAT entirely for the relevant taxable year.
We do not currently have all data necessary to compute PPC's actual base erosion percentage for TY 2018, 2019, and 2020. To complete this computation, we need to request the following from Marcus Whitfield (VP, Global Tax, PPC) and from Crestfield & Associates (Martin Ogilvy, engagement partner, and Susan Lam, transfer pricing partner):
• PPC's total deductions for each year as reported on Form 1120;
• Identification and quantification of all deductible payments from PPC to related foreign parties for each year;
• PPC's completed Form 8991 (Tax on Base Erosion Payments of Taxpayers With Substantial Gross Receipts) for each year, if filed; and
• Any internal analysis or workpapers supporting PPC's BEAT position for each year.
Preliminary Assessment. Given the intercompany structure described above — in which PBI pays PPC rather than the reverse — PPC's base erosion percentage is likely low, potentially falling below the 3% threshold. If confirmed, this would render BEAT inapplicable to PPC for the years at issue, and the entire BEAT analysis would serve as a defensive shield rather than a source of liability.
D. Impact of § 482 Adjustments on BEAT Position
1. Scenario: IRS Adjustments Sustained in Full ($380.4M Net). If the IRS's proposed § 482 adjustments are sustained in full, PPC's income increases (through higher royalty receipts and higher cost-sharing receipts from PBI). This has two consequences for BEAT:
• Regular Tax Liability Increases. PPC's regular U.S. tax liability increases because its taxable income rises by the amount of the adjustments. The BEAT minimum tax applies only to the extent it exceeds regular tax liability. Higher regular tax liability makes it less likely that the BEAT minimum tax is binding.
• MTI and Regular Taxable Income Increase by the Same Amount. The proposed adjustments add income to PPC; they do not add base erosion deductions. Accordingly, both MTI and regular taxable income increase by the same dollar amount. The BEAT computation (BEAT rate × MTI minus regular tax) is not adversely affected because the MTI increase is matched by the regular taxable income increase and corresponding regular tax increase.
In sum, if the § 482 adjustments are sustained, BEAT liability is unlikely to be triggered or increased. The adjustments move PPC further away from BEAT liability, not toward it.
2. Scenario: IRS Recharacterizes CSA or Challenges PBI's Substance Entirely. A more aggressive scenario would arise if the IRS were to disregard PBI entirely — for example, by asserting that PBI lacks economic substance under the DEMPE (Development, Enhancement, Maintenance, Protection, and Exploitation) framework, and that all income currently reported by PBI should be attributed to PPC. In this scenario:
• All of PBI's income (€2.14 billion in FY 2020) would be attributed to PPC, dramatically increasing PPC's U.S. taxable income.
• The base erosion payment analysis would fundamentally change because there would be no related foreign party to receive base erosion payments (if PBI is disregarded, payments to PBI would be disregarded as well).
• The GILTI inclusion would be eliminated (if PBI is disregarded, there is no CFC and no GILTI), but the income would be taxed at 21% in full with no § 250 deduction offset.
However, the NOPA does not fully disregard PBI. The IRS examination team proposes adjustment of intercompany pricing, not entity disregard. The NOPA acknowledges PBI as a separate entity and adjusts the terms of transactions between PPC and PBI within the § 482 framework. While certain language in the NOPA alludes to concerns about PBI's economic substance — reflecting the examination team's partial skepticism about PBI's functional contribution to intangible development — the NOPA stops short of a full entity-disregard position.
PBI's economic substance is supported by substantial evidence, including:
• 185 employees as of December 31, 2020 (up from 52 at incorporation in 2012);
• 42 board of directors meetings held in Dublin during 2017–2020;
• Cumulative regulatory expenditures of €47.2 million, reflecting PBI's active engagement with the EMA and other non-Americas regulatory authorities;
• Approximately 18,000 square feet of office space at the Sandyford Business Park;
• Independent pricing authority across 68 country markets;
• A full-time managing director, Aidan Naughton, based in Dublin; and
• Separate and substantial contract manufacturing operations through PMI (620 employees, Ringaskiddy facility).
3. Interaction Between GILTI and BEAT. Both GILTI and BEAT modify PPC's U.S. tax computation, but they do so in different ways and through different mechanisms.
If PPC's GILTI inclusion increases PPC's regular tax liability (because GILTI is included in gross income under IRC § 951A and taxed at the effective GILTI rate), this makes it less likely that the BEAT minimum tax exceeds regular tax. The BEAT minimum tax is a floor, not an additional tax — BEAT applies only to the extent it exceeds regular tax. Higher regular tax (from GILTI inclusions) raises the floor that BEAT must exceed.
Net conclusion: The proposed § 482 adjustments are substantially more likely to affect PPC's GILTI position than its BEAT position. The GILTI analysis is quantitatively significant, while the BEAT analysis is expected to yield nil or minimal impact given PPC's inbound-payment intercompany structure.
E. Strategic Implications for Defense
The BEAT analysis supports PPC's broader position that its international IP structure does not erode the U.S. tax base in the manner Congress targeted when it enacted BEAT. The royalty and cost-sharing payment flows are inbound to PPC — PBI pays PPC, not the other way around. This distinguishes PPC's structure from the prototypical base-eroding structure in which a U.S. taxpayer makes deductible payments (royalties, management fees, interest) to related foreign entities, reducing its U.S. taxable income.
If PPC's base erosion percentage is confirmed to be below 3%, PPC can make a contextual argument that its intercompany structure is inherently non-abusive as measured by Congress's own filter. The BEAT was designed to catch structures that strip income from the U.S. tax base through excessive outbound deductible payments. PPC's structure passes the BEAT test, which — while not dispositive on the separate question of arm's-length pricing under IRC § 482 — provides useful contextual support for the reasonableness of PPC's transfer pricing positions.
This argument is most appropriately deployed at the Appeals stage, where the Appeals Officer may consider the broader economic and policy context of the dispute. The argument carries less weight at the examination stage, where the IRS team is focused on the technical arm's-length analysis, and carries no weight in litigation, where the arm's-length standard is applied without reference to the taxpayer's BEAT profile. Nevertheless, the BEAT analysis is a valuable data point in the engagement team's overall strategy and should be included in Appeals presentations and settlement memoranda.
V. Combined GILTI/BEAT Quantitative Impact Model (TY 2018–2020)
A. Summary Table of Interactions
The following table summarizes the interaction of the proposed IRC § 482 adjustments with PPC's GILTI and BEAT positions for TY 2018, 2019, and 2020. All amounts are in millions of dollars. These computations are illustrative and are subject to refinement upon receipt of PPC's filed GILTI computations and BEAT filings.
¹ Correlative offset allocated illustratively based on proportional share of gross adjustments; actual allocation to be confirmed from NOPA workpapers. ² Approximate; subject to confirmation of year-by-year correlative offset allocation. ³ Assumes dollar-for-dollar reduction in PBI tested income from increased deductible payments to PPC. ⁴ Assumes PBI's blended effective Irish rate is approximately 6.25% (KDB-heavy), yielding residual GILTI rate of approximately 5.5%. ⁵ Computations will differ if PBI's blended Irish rate is higher than 6.25% (e.g., closer to 12.5%), which would increase GILTI tax savings and reduce net incremental tax.